

Message

From: eu-toxrisk-sab-request@eurtd.com [eu-toxrisk-sab-request@eurtd.com]
on behalf of Thomas Steger-Hartmann [thomas.steger-hartmann@bayer.com]
Sent: 5/22/2017 2:17:51 PM
To: Henrik Appelgren [Henrik.Appelgren@kemi.se]; Water, B. van de [water_b@lacdr.leidenuniv.nl]; Benjamin Barton [barton@arttic.eu]; eu-toxrisk-sab@eurtd.com
Subject: RE: New job

Dear Henrik

First of all congratulations!

My take would be that the appointment to the SAB is related to the expert and not to his position, i.e. I'd like to keep you on board, as long as there is no Conflict of Interest.

Eventually it is up to the SteerCo to decide.

Kind regards

Thomas

Bayer: Science For A Better Life

Bayer AG

Drug Discovery, Pharmaceuticals

Investigational Toxicology

Berlin: Building S116, 523

13342 Berlin, Germany

Tel: +49 30 468-14256

Fax: +49 30 468-18172

Mobile: +49 170 3326034

Wuppertal: Building 514, 301

Tel: +49 202 36-4997

E-mail: thomas.steger-hartmann@bayer.com

Web: <http://www.bayer.com>

Vorstand: Werner Baumann, Vorsitzender | Liam Condon, Johannes Dietsch, Hartmut Klusik, Kemal Malik, Erica Mann, Dieter Weinand

Vorsitzender des Aufsichtsrats: Werner Wenning

Sitz der Gesellschaft: Leverkusen | Amtsgericht Köln, HRB 48248

From: eu-toxrisk-sab-request@eurtd.com [mailto:eu-toxrisk-sab-request@eurtd.com] **On Behalf Of** Henrik Appelgren
Sent: Montag, 22. Mai 2017 15:08
To: Water, B. van de; Benjamin Barton; eu-toxrisk-sab@eurtd.com
Subject: New job

Dear All,

I hope that things are fine with all of you.

This is to let you know that I have a new employment starting from September 4. I received an offer to work as Chief Scientific Officer at SenzaGen (<http://senzagen.com>). They have close collaboration with a group at Lund University. They have developed the assay Genomic Allergen Rapid Detection (GARD). We (SE) are lead country for this project in the OECD test guideline-programme. The GARD assay has prediction values of 90 %, which can be compared with the in vivo Local Lymph Node Assay (LLNA), which has only about 72%. GARD can also assess potency (category 1A and 1B),

which is important for specific concentration limits in products. GARD can also assess substances that require activation (pre and prohapens) in order to exhibit their sensitisation properties. GARD is a very good example when new methods are better than the current ones!

However, sensitisation is not one of the focus areas for EUToxRisk.

This may of course have some impact on my position in the EUToxRisk SAB. Currently I do not know what will happen. SenzaGen has nothing against my position in the SAB, but I will no longer be a regulator (not for a while at least). However, I still have 15 years of experience from a regulatory agency.

I leave it to the steering team to decide.

Best regards

Henrik

Henrik Appelgren
National Coordinator OECD testguidelines, PhD
Proposals for Classification and Restriction
Swedish Chemicals Agency
Direct: +46 8 519 41 248
Tel: +46 8 519 41 100
www.kemikalieinspektionen.se